Bowel Prep No Better Than Fasting Before Capsule Endoscopy For Obscure Gi Bleeding

Given Imaging Announces New Studies That Affirm PillCam SB as the Gold Standard for Detecting and Diagnosing Small Bowel Diseases





"We found that there was no difference observed for cleanliness and visibility between the group that was given oral sodium phosphate and the group that fasted. Therefore, our study concludes that oral sodium phosphate cannot be recommended for CE exploration in patients with obscure GI bleeding." Patients and Methods A total of 129 patients with obscure GI bleeding were enrolled in this prospective, multicenter, controlled trial study between December 2004 and February 2006. The patients (53 men and 76 women with a median age of 56.9 years), were randomized into two groups. In group A, the patients were instructed to consume only clear liquids during the evening before the procedure, followed by an eight-hour fast. In group B, patients were asked to drink 45 mL of oral sodium phosphate with a glass of water the evening before and the morning of the procedure by using at least 2 L of clear liquid until midnight. Only a three-hour fast was required in group B. After swallowing the capsule, the patients were not to drink for two hours and not eat for four hours regardless of randomization. Iron supplements and vegetal charcoal were stopped eight days before CE examination to avoid black stool residue. No added prokinetic drug was used. Sixteen experienced investigators in eight centers, blinded to the randomization, independently evaluated the CE images. Gastric emptying time (i.e., the time from the first gastric image to the time of the first duodenal image), small bowel transit time (i.e., the time from the first duodenal image to the time of the first cecal image), and whether or not the cecum was reached were recorded for each patient. Because a universally accepted scale for grading bowel cleanliness is lacking, researchers developed their own scale, assessing preparation at five different segments: duodenum, jejunum, middle small bowel, ileum and distal ileum. look at more info http://www.endonurse.com/news/2008/06/bowel-prep-no-better-than-fasting-before-capsule.aspx







Studies Confirming Efficacy of PillCam SB for Detecting Small Bowel Diseases Presented at UEG Week





The results, which represent the largest cohort of pediatric patients and include the youngest child ever to undergo capsule endoscopy, demonstrated that with careful selection, CE is a useful and safe diagnostic modality in children with suspected small bowel diseases. "Why Should We Still Use Capsule Endoscopy in Inflammatory Bowel Disease," oral presentation OP430: presented by Lucia Marquez M.D., and colleagues, Hospital del Mar, Digestive Diseases, Barcelona, Spain, analyzed the impact of PillCam capsule endoscopy (CE) on the diagnosis and management of suspected or established Inflammatory Bowel Disease (IBD). Results confirmed that CE findings led to a new diagnosis in over 40% of cases and that CE is a useful tool for diagnosis of new IBD as well as for guiding treatment. "Findings and Long Term Outcomes for Patients Following Video Capsule Endoscopy to Investigate Iron Deficiency Anemia," poster P1336: presented by Janisha Patel M.D., and colleagues, Kings College Hospital, Dept. of Hepatology, London, United Kingdom, observed long term outcomes in patients who have undergone capsule endoscopy to investigate iron deficiency anemia (IDA). The results of this retrospective study analyzing long term outcomes of 115 patients who had a negative upper and lower GI endoscopy, showed capsule endoscopy (CE) presented relevant findings in over 50% of patients who underwent CE to investigate unexplained IDA and a significant number of these patients were then actively treated. "Emergency Video Capsule Endoscopy in Patients with Acute Gastrointestinal Bleeding, poster," poster P1332:presented by Christoph Schlag M.D., and colleagues, Technical University Munich, Munich, Germany, analyzed the use of PillCam capsule endoscopy (CE) for acute gastrointestinal bleeding in the emergency setting. Of the patients who failed to have their source of bleeding identified with gastroscopy, 93% showed complete examination using emergency CE and 73% had the bleeding source identified with CE. Results confirm that for patients with signs of acute upper/mid gastrointestinal bleeding who have had a negative gastroscopy, emergency CE can be used to immediately detect the bleeding source and to guide therapy. About UEG Week UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning. find more http://www.azooptics.com/news.aspx?newsID=18030











The risks of PillCam capsule endoscopy include capsule retention, aspiration and skin irritation. Endoscopic placement may present additional risks. Medical, endoscopic, or surgical intervention may be necessary to address any of these complications, should they occur. About Given Imaging Since pioneering the field of capsule endoscopy in 2001, Given Imaging has become a world leader in GI medical devices, offering health care providers a range of innovative options for visualizing, diagnosing and monitoring the digestive system. The company offers a broad product portfolio including PillCam(R) capsule endoscope for the small bowel, esophagus and colon. The company also offers industry-leading GI functional diagnostic solutions including ManoScan(R) high resolution manometry, Bravo(R) capsule-based pH monitoring, Digitrapper(R) pH-Z monitoring, and SmartPill(R) motility monitoring systems. Given Imaging is committed to delivering breakthrough innovations to the GI community and supporting its ongoing clinical needs. Given Imaging's headquarters are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia, Vietnam, Hong Kong and Brazil. For more information, please visit givenimaging.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Such forward-looking statements include statements relating to the Company exploring strategic alternatives and considering possible strategic transactions involving the Company. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to successfully complete any necessary or required clinical studies with our products, (3) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (4) our success in implementing our sales, marketing and manufacturing plans, (5) the level of adoption of our products by medical practitioners, (6) the emergence of other products that may make our products obsolete, (7) lack of an appropriate bowel preparation materials to be used with our PillCam COLON capsule, (8) protection and validity of patents and other intellectual property rights, (9) the impact of currency exchange rates, (10) the effect of competition by other companies, (11) the outcome of significant litigation, (12) our ability to obtain reimbursement for our product from government and commercial payors, (13) quarterly variations in operating results, (14) the possibility of armed conflict or civil or military unrest in Israel, (15) the impact of global economic conditions, (16) our ability to successfully integrate acquired businesses, (17) changes and reforms in applicable healthcare laws and regulations, (18) quality issues and adverse events related to our products, such as capsule retention, aspiration and failure to attach or detach, bleeding or perforation that could require us to recall products and impact our sales and net income, and (19) other risks and factors disclosed in our filings with the U.S. find out here http://www.marketwatch.com/story/given-imaging-announces-new-studies-that-affirm-pillcam-sb-as-the-gold-standard-for-detecting-and-diagnosing-small-bowel-diseases-2013-10-15